Published in Sci Rep on November 14, 2016
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
Genome-scale CRISPR-Cas9 knockout screening in human cells. Science (2013) 12.36
Genetic screens in human cells using the CRISPR-Cas9 system. Science (2013) 10.75
Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med (2012) 8.08
Human polyomavirus JC virus genome. J Virol (1984) 5.87
Seroepidemiology of human polyomaviruses. PLoS Pathog (2009) 4.62
Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol (2003) 3.73
Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med (2010) 3.16
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev (2012) 2.92
Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. J Virol (1990) 2.58
Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep (2013) 2.48
Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol (2010) 2.48
The role of polyomaviruses in human disease. Virology (2008) 2.41
Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature (2014) 2.33
Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med (1988) 2.32
Infection of human polyomaviruses JC and BK in peripheral blood leukocytes from immunocompetent individuals. Virology (1994) 1.70
The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids (2014) 1.46
Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate. J Virol (2010) 1.41
Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun (2015) 1.41
The length of vesicular stomatitis virus particles dictates a need for actin assembly during clathrin-dependent endocytosis. PLoS Pathog (2010) 1.40
CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. Biotechnol J (2014) 1.34
Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids (2014) 1.33
Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis (2011) 1.32
Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology (2014) 1.29
The human JC polyomavirus (JCPyV): virological background and clinical implications. APMIS (2013) 1.28
Transcriptional regulation: lessons from the human neurotropic polyomavirus, JCV. Virology (1995) 1.27
Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. J Virol (2014) 1.26
Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther (2015) 1.17
Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J Clin Microbiol (1997) 1.14
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep (2015) 1.14
CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells. J Gen Virol (2014) 1.12
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol (2016) 1.11
RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A (2014) 1.10
Detection of JC virus DNA in the peripheral blood leukocytes of HIV-infected patients. AIDS (1996) 1.02
A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector. PLoS One (2015) 1.01
A retrograde trafficking inhibitor of ricin and Shiga-like toxins inhibits infection of cells by human and monkey polyomaviruses. MBio (2013) 1.00
Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res (2015) 0.99
JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route. J Virol (2014) 0.95
Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome. J Gen Virol (2015) 0.93
CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection. PLoS One (2015) 0.90
Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment. Virology (2015) 0.90
Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells. Biomed Res Int (2014) 0.87
HIV Excision Utilizing CRISPR/Cas9 Technology: Attacking the Proviral Quasispecies in Reservoirs to Achieve a Cure. MOJ Immunol (2014) 0.85
The therapeutic application of CRISPR/Cas9 technologies for HIV. Expert Opin Biol Ther (2015) 0.83
Genome engineering using Adeno-Associated Virus (AAV). Methods Mol Biol (2015) 0.82
[The application of CRISPR-Cas9 gene editing technology in viral infection diseases]. Yi Chuan (2015) 0.78
NRP2 and CD63 Are Host Factors for Lujo Virus Cell Entry. Cell Host Microbe (2017) 0.75